Evotec's Transition Year Tests Investor Patience with Ambitious Long-Term Plan

Evotec's 2025 revenue fell slightly to €788.4M, with biologics up 40%. Adjusted EBITDA doubled, but a weak 2026 forecast sent shares tumbling.

The financial results for 2025 presented by Evotec on April 8 delivered a mixed bag: operational progress overshadowed by a sobering forecast. While the company hit the upper end of its own guidance, the outlook for 2026 has left the market wanting more, sending shares to a level roughly 23 percent below their 200-day moving average at 4.53 euros.

Group revenue for the year dipped slightly to 788.4 million euros, a 1.1 percent decrease from the prior year. This top-line figure masks a stark divergence between its business units. The core Drug Discovery and Preclinical Development segment saw revenue decline by 13.5 percent to 528.9 million euros, pressured by a weak market for early-stage research. In contrast, the Just – Evotec Biologics unit surged approximately 40 percent to about 259 million euros. A strong fourth quarter provided a bright spot, with revenue climbing 14.5 percent to 253.3 million euros and the company posting a positive earnings per share of 0.09 euros, a significant reversal from a 0.23 euro loss in the same period a year earlier.

Cost discipline and a one-time payment yielded significant bottom-line improvements. Adjusted EBITDA more than doubled, rising from 22.6 million euros to 41.1 million euros, a figure that slightly exceeded analyst expectations. This jump was driven by cost-saving measures and a 65 million euro license payment from the Sandoz agreement. Consequently, the net loss was halved to just under 104 million euros. Year-end liquidity stood at a solid 476.4 million euros, providing a buffer for the ongoing transformation.

It is the forward guidance that has disappointed. For 2026, management forecasts revenue between 700 and 780 million euros and an adjusted EBITDA ranging from zero to 40 million euros. This outlook falls well short of the average analyst expectation for EBITDA of around 80.8 million euros. The company explicitly labels 2026 a transition year within its broader "Horizon" transformation program. This strategic overhaul aims to consolidate global operations into ten Centers of Excellence and reduce the annual cost base by approximately 75 million euros by the end of 2027. Management anticipates tangible improvements will become more evident in the second half of the coming year.

Additional liquidity is already on the horizon. From the acquisition of its stake in Tubulis by Gilead Sciences, Evotec expects an upfront payment of around 100 million US dollars in the second quarter of 2026, with the potential for up to an additional 58 million dollars upon achieving certain milestones.

Leadership changes accompany this strategic shift. Since April 1, Dr. Ashiq H. Khan has served as Chief Commercial Officer, bringing over 15 years of experience in AI-driven platform businesses and a track record of deals worth more than $7 billion. At the supervisory board level, Dieter Weinand, a former executive at Bayer, Pfizer, and Sanofi, is proposed to be elected as the new chairman at the Annual General Meeting on June 11.

Analyst opinions reflect the current uncertainty. RBC Capital Markets maintains an "Outperform" rating with a price target of 10.00 euros, suggesting more than double the current share price. Van Lanschot Kempen offers a more cautious target of 6.00 euros. The company's own medium-term ambitions are clear: it is targeting group revenue exceeding one billion euros by 2030 and aims for an adjusted EBITDA margin surpassing 20 percent by 2028. The success of the "Horizon" plan in bridging the current valuation gap will be critically tested as 2026 progresses.